Recent Quotes
My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Teva Pharmaceutical Industries Limited American Depositary Shares (NY:TEVA)

19.78 +0.17 (+0.87%)
Official Closing Price Updated: 7:00 PM EDT, Oct 28, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Teva Pharmaceutical Industries Limited American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
SciSparc Expands Biotech Ambitions, Buys Stake In Miza III Ventures
SciSparc traded higher after the company announced it had signed a definitive agreement to acquire a controlling stake in Miza III Ventures. 
Via Benzinga
Billionaire Stanley Druckenmiller Is Selling Nvidia and Palantir and Piling Into One of Wall Street's Hottest Drug Stocks Ahead of 2026
Druckenmiller is considered one of the best investors of all time. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Teva, Viatris On Investor Watch As White House Spares Generic Drugs From Tariffs
The Trump administration backs off plans to impose tariffs on generic drugs after internal debate over price impacts and supply concerns. 
Via Benzinga
Topics Government World Trade
SciSparc And AutoMax Call Off Merger
SciSparc ends merger with AutoMax, sets loan repayment terms, and refocuses on CNS drug development and innovation. 
Via Benzinga
This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More
Via Stocktwits
Earnings Scheduled For July 30, 2025
 
Via Benzinga
How Do Investors Really Feel About Teva Pharmaceutical Indus?
 
Via Benzinga
Billionaire Stanley Druckenmiller Sold His Fund's Stakes in Nvidia and Palantir, and Has Piled Into These 2 Phenomenal Stocks for 4 Straight Quarters
Duquesne Family Office's billionaire boss bid adieu to Wall Street's hottest AI stocks in favor of another trillion-dollar company and a long-awaited turnaround story in the healthcare sector. 
Via The Motley Fool
Topics Artificial Intelligence Supply Chain
Is Teva Pharmaceutical Indus Gaining or Losing Market Support?
 
Via Benzinga
Trump Administration To Unveil Tylenol-Autism Review, Tout This Drug As Potential Treatment: Report
Trump administration to announce concerns about Tylenol use in pregnancy and potential treatment for autism, in line with President's priority. 
Via Benzinga
Topics Government
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?
Are the Dow's biggest yields a bargain or a warning sign? Here's how the top payouts stack up, and what that could mean for income investors. 
Via The Motley Fool
Topics Stocks
US-India Trade War Escalates: New Tariffs Spark Inflation Fears and Corporate Profit Warnings
The global trade landscape has once again been rattled as the United States officially implemented sweeping new tariffs on a significant portion of imports from India. Effective August 27, 2025, these... 
Via MarketMinute
Topics Economy Government Supply Chain
Teva Launches Generic GLP-1 Weight Loss Drug With FDA Nod For Saxenda
Teva launches the first U.S. generic version of Saxenda for weight loss after FDA approval, expanding its portfolio with a key GLP-1 therapy. 
Via Benzinga
FDA Approves First-Ever Generic Weight-Loss Drug In A Blow To Novo Nordisk
Teva Pharmaceutical is joining compounders, knocking off one of Novo Nordisk's weight-loss drugs. 
Via Investor's Business Daily
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
Billionaire Stanley Druckenmiller Sold All of His Palantir and Has Piled Into This High-Flying Drug Stock for 4 Consecutive Quarters
Duquesne's billionaire boss bid adieu to Wall Street's hottest artificial intelligence (AI) stock in favor of one of the cheapest pharmaceutical stocks on the planet. 
Via The Motley Fool
Topics Artificial Intelligence
How Is The Market Feeling About Teva Pharmaceutical Indus?
 
Via Benzinga
Teva Pharma Boosts Outlook For Key Innovative Drugs Austedo, Ajovy, Uzedy
Teva raised 2025 guidance for Austedo, Ajovy, and Uzedy after Q2 earnings beat estimates, despite missing revenue expectations. 
Via Benzinga
Topics Earnings
Why Drugmaker Teva Pharmaceutical Narrowed Full-Year Guidance After Beating Q2 Earnings
Teva stock is trading below key levels. 
Via Investor's Business Daily
Generic Revlimid Fades, But Teva's Broader Generics Outlook Remains Strong
Teva anticipates EBITDA recovery post-2025 as Austedo and Uzedy grow and generic Revlimid faces rising competition. 
Via Benzinga
A Glimpse of Teva Pharmaceutical Indus's Earnings Potential
 
Via Benzinga
Billionaire Stanley Druckenmiller Sold His Entire Stake in Palantir and Has Loaded Up on These 2 Exceptional Stocks for 3 Consecutive Quarters
Duquesne Family Office's billionaire chief dumped his fund's stake in Wall Street's artificial intelligence (AI) darling in favor of two reasonably cheap stocks that have taken off in recent years. 
Via The Motley Fool
Topics Artificial Intelligence
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Looking Into Teva Pharmaceutical Indus's Recent Short Interest
 
Via Benzinga
What Analysts Are Saying About Teva Pharmaceutical Indus Stock
 
Via Benzinga
Billionaire Stanley Druckenmiller Loaded Up on These 3 Stocks. Are They Buys?
Via The Motley Fool
Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters
Duquesne Family Office's billionaire chief sold every share of Wall Street's hottest artificial intelligence (AI) stock in favor of a drugmaker whose shares have surged 142% in two years. 
Via The Motley Fool
Topics Artificial Intelligence Economy
Goldman Sachs Bullish On Branded Drug Upside At Teva: What About Viatris?
Goldman Sachs initiates Teva, Viatris, and Amneal, highlighting branded growth and pipeline strength, but one company's unclear outlook. 
Via Benzinga
9 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Teva Reaffirms Growth Strategy, Eyes $5 Billion Innovative Franchise By 2030
Teva outlines its accelerated growth strategy focused on innovation, aiming for $5 billion in biopharma revenue by 2030, while maintaining a strong generics and biosimilars base. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.